Pharmacist-backed picks help families manage fever and pain, seasonal allergies, and cough and congestion as kids head back to the classroom.
|Articles|March 3, 2008
CDC expands recommended pediatric age range for influenza vaccine
The Centers for Disease Control & Prevention recommends influenza vaccine for all children six months to 18 years old.
Advertisement
The CDC's Advisory Committee on Immunization Practices (ACIP) has unanimously voted to expand the recommended age range for annual influenza immunization to include all children six months of age to 18 years old. The vote was taken at an agency meeting in Atlanta in February and will increase the number of children needing the vaccine by about 30 million. The
Advertisement
Related to this article
This episode breaks down how PBMs conduct inventory audits, the sourcing and timing issues that trigger recoupments, and how pharmacies can prepare and push back.
In part 2 of our discussion with Kimberly Kue-Tsemo, PharmD, she addresses the emergence of technology and the nuances behind its actual capabilities.
In part 2, Allison Schneider, MPH, discusses PBM and 340B reform that could compound pharmacies’ burden amid ongoing Medicare drug price negotiations.
Researchers provide an update on the adverse events of special interest following patients who received 2024–2025 Pfizer-BioNTech COVID-19 vaccination.
Type 1 and type 2 diabetes reports emphasize areas where pharmacists can act now, including CGM, cardio-kidney therapies, and equitable patient access.
Kimberly Kue-Tsemo, PharmD, explores the current state of US pharmacy deserts amid ongoing reform, evolution in practice, and more.
Alyssa Eisenberg, PharmD, discusses key industry challenges and developments as community pharmacists continue to impact patient outcomes across the US.
Advertisement
Advertisement
Trending on Drug Topics
1
Updated Diabetes Consensus Shifts Focus from Glucose Control to Whole-Person Care
2
What the CLARITY Study Means for Counseling on Long-Acting HIV PrEP
3
Q&A: Overlapping PBM, 340B Reform Create Uncertainty for Pharmacies
4
No Added Adverse Event Risk in Pfizer-BioNTech COVID-19 Vaccine
5